---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-121677"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:09:21.846432+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences closes $69.9M public offering of common stock and warrants

## Summary
- Sold 11.7M shares, 3.6M pre-funded warrants, and 3.8M common stock warrants at $4.90 combined price.
- Net proceeds of approximately $69.9 million after underwriting discounts and expenses.
- Proceeds to advance clinical programs in choroidal melanoma, ocular surface cancers, and bladder cancer.
- Cash runway extended into the first half of 2027.
- Offering closed on May 16, 2025.

## SEC filing metadata
- accession: 0001193125-25-121677
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312525121677/0001193125-25-121677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312525121677/d213451d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-121677
- JSON: https://secwatch.observer/filing/0001193125-25-121677.json
- Plain text: https://secwatch.observer/filing/0001193125-25-121677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.